Top

Published in:

01-05-2017 | Bone and Soft Tissue Sarcomas

Are We Allowed to Limit Surgical Aggressiveness With Small Rectal Gastrointestinal Stromal Tumors?

Authors: Marco Fiore, MD, Chandrajit P. Raut, MD, MSc, Alessandro Gronchi, MD

Published in: Annals of Surgical Oncology | Issue 5/2017

Excerpt

This Annals of Surgical Oncology issue includes a retrospective study evaluating the role of neodjuvant therapy and different surgical approaches in the management of anorectal gastrointestinal stromal tumors (GISTs).1 This is the largest series of anorectal GISTs reported to date, obtained from the National Cancer Data Base (NCDB), which includes more than 1500 centers in the United States. …

Hawkins AT, Wells KO, Krishnamurty DM, et al. Preoperative chemotherapy and survival for large anorectal GIST: a national analysis of 333 cases. Ann Surg Oncol. 2016. doi:10.1245/s10434-016-5706-1.

Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol. 2009;35:739–45.CrossRefPubMed

Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.CrossRefPubMedPubMedCentral

Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol. 2016;34:244–50.CrossRefPubMed

Casali PG, Le Cesne A, Poveda Velasco A, et al. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol. 2015;33:4276–83.CrossRefPubMed

Gronchi A, Raut CP. The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. Ann Surg Oncol. 2012;19:1051–5.CrossRefPubMed

Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, Gronchi A, Hohenberger P. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. Ann Surg Oncol. 2013;20:586–92.CrossRefPubMed

Title: Are We Allowed to Limit Surgical Aggressiveness With Small Rectal Gastrointestinal Stromal Tumors?
Authors: Marco Fiore, MD
Chandrajit P. Raut, MD, MSc
Alessandro Gronchi, MD
Publication date: 01-05-2017
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue 5/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-016-5710-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Are We Allowed to Limit Surgical Aggressiveness With Small Rectal Gastrointestinal Stromal Tumors?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2017

Questioning the Quality of Thyroid Cancer Data: Thoughts from the Commission on Cancer and the National Cancer Database

The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer

Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer

The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors

Intraperitoneal Administration of Plasma-Activated Medium: Proposal of a Novel Treatment Option for Peritoneal Metastasis From Gastric Cancer

An Optimal Approach for Laparoscopic D3 Lymphadenectomy Plus Complete Mesocolic Excision (D3+CME) for Right-Sided Colon Cancer